You are here

Our science / Clinical Trials / Find a Trial / NCT00234338

Study Evaluating Prevenar in High-Risk Children

Back to Search Print Save as PDF Bookmark Trial

NCT00234338

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Frankfurt, , 60590 Germany
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-5 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- High-risk children ages 2 to 5 years old

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior administration of Prevenar

- Prior and/or concurrent administration of 23 vPs vaccine

NCT00234338
Pfizer
Completed
Study Evaluating Prevenar in High-Risk Children

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC)
Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
NCT03801928
All Genders
18+
Years
Columbia, Maryland
Meningococcal B Disease
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
NCT02534935
All Genders
1+
Years
Multiple Sites
Intra-Abdominal Infections, Infectious Skin Disease
Tygacil Drug Use Investigation
NCT01789905
All Genders
Parkinson Disease
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
NCT02687542
All Genders
40+
Years
Multiple Sites
Study Evaluating Prevenar in High-Risk Children
Prospective Post-Marketing Surveillance Study of Prevenar in High-Risk Children Aged 2 to 5 Years
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Pneumococcal Disease
Not Provided
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
5000
April 2007
Not Provided

Inclusion Criteria:

  • High-risk children ages 2 to 5 years old

Exclusion criteria:

  • Prior administration of Prevenar
  • Prior and/or concurrent administration of 23 vPs vaccine
Sexes Eligible for Study: All
2 Years to 5 Years   (Child)
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00234338
101850
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Germany, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now